ArticleBiosensors2022
Label-Free Immunosensor Based on Polyaniline-Loaded MXene and Gold-Decorated β-Cyclodextrin for Efficient Detection of Carcinoembryonic Antigen.
Article in Biosensors, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed.
- Electrochemical biosensing of alpha-fetoprotein based on carboxylated multi-walled nanotube-polyAzur A (in DES)-gold nanoparticles.Turkish journal of chemistry · 2026Article
- Ultrasensitive electrochemical biosensor based on MXene quantum dots for prostate cancer biomarker detection.Scientific reports · 2025Article
- MXene-based electrochemical sensors for cancer biomarker detection: current trends, challenges, and future directions.Mikrochimica acta · 2025Review
- MXenes as emerging materials to repair electroactive tissues and organs.Bioactive materials · 2025Review
- Article
- Construction of electrochemical immunosensor from MXene/multi-walled carbon nanotubes/gold nanoparticles for specific detection of carcinoembryonic antigen.Mikrochimica acta · 2024Article
- Electrochemical protein biosensors for disease marker detection: progress and opportunities.Microsystems & nanoengineering · 2024Review
- Not Only Graphene Two-Dimensional Nanomaterials: Recent Trends in Electrochemical (Bio)sensing Area for Biomedical and Healthcare Applications.Molecules (Basel, Switzerland) · 2023Review
- Development of Two-Dimensional Functional Nanomaterials for Biosensor Applications: Opportunities, Challenges, and Future Prospects.Nanomaterials (Basel, Switzerland) · 2023Review
- Highly Sensitive Immunosensing of Carcinoembryonic Antigen Based on Gold Nanoparticles Dotted PB@PANI Core-Shell Nanocubes as a Signal Probe.Journal of analytical methods in chemistry · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Multiple strategies have been employed to improve the performance of label-free immunosensors, among which building highly conductive interfaces and introducing suitable biocompatible carriers for immobilizing antibodies or antigens are believed to be efficient in most cases. Inspired by this, a label-free immunosensor for carcinoembryonic antigen (CEA) detection was constructed by assembling AuNPs and β-CD (Au-β-CD) on the surface of FTO modified with PANI-decorated f-MXene (MXene@PANI). Driven by the high electron conductivity of MXene@PANI and the excellent capability of Au-β-CD for antibody immobilization, the BSA/anti-CEA/Au-β-CD/MXene@PANI/FTO immunosensor exhibits balanced performance towards CEA detection, with a practical linear range of 0.5-350 ng/mL and a low detection limit of 0.0429 ng/mL. Meanwhile, the proposed sensor presents satisfying selectivity, repeatability, and stability, as well as feasibility in clinic serum samples. This work would enlighten the prospective research on the alternative strategies in constructing advanced immunosensors.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.